Chlamydia and gonorrhea are the most prevalent, treatable STDs*. If left untreated, complications can include infertility, pelvic inflammatory disease, pregnancy complications.2,3ECDC recommends:
- Routine screening of Chlamydia and gonorrhea on an annual basis is recommended for all sexually active females aged <25 years1
- Chlamydia and gonorrhea screening have been extended to young men in some countries
- NAATs^ are the recommended diagnosis for chlamydia and gonorrhea4
- Same-day testing and treatment
- Full STI screen at baseline including NAAT^ testing for gonococcal and chlamydial infections at sites of exposure (genital, rectal, pharyngeal) and syphilis serology
- 3-monthly screening for bacterial STIs (chlamydia, gonorrhoea and syphilis) for individuals receiving PrEP#, especially for MSM and transwomen
* STD — Sexually Transmitted Diseases
^ NAAT — Nucleic Acid Amplification Test
# PrEP — Pre-Exposure Prophylaxis
(1) 2015 European Guideline on the Management of Chlamydia Trachomatis Infections. Euro Surveill. 2015;20(48):30080.
(2) WHO Guidelines for the Treatment of Chlamydia Trachomatis. Accessed Jun 2020. https://apps.who.int/iris/bitstream/handle/10665/246165/9789241549714-eng.pdf?sequence=1
(3) WHO Guidelines for the Treatment of Neisseria gonorrhoeae. Accessed Jun 2020. https://apps.who.int/iris/bitstream/handle/10665/246114/9789241549691-eng.pdf?sequence=1
(4) 2012 European Guideline on the Diagnosis and Treatment of Gonorrhoea in Adults. Int J STD AIDS. 2013 Feb;24(2):85-92.
(5)BHIVA/BASHH Guidelines on the Use of HIV Pre-Exposure Prophylaxis (PrEP) 2018. HIV Med. 2019 Mar;20 Suppl 2:s2-s80.